A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.
Clinical trial NCT06654947 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06654947
- Sponsor
- Fujian Cancer Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-01-01
- Primary completion
- 2026-12-01
- Enrollment
- 23
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.